Nair Anroop B, Kumar Sunil, Dalal Pooja, Nagpal Chahat, Dalal Sweta, Rao Rekha, Sreeharsha Nagaraja, Jacob Shery
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Hofuf 31982, Al-Ahsa, Saudi Arabia.
Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar 125001, India.
Pharmaceutics. 2022 Feb 9;14(2):383. doi: 10.3390/pharmaceutics14020383.
Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed.
银屑病和湿疹等皮肤疾病与皮肤的化学和分子组成改变有关。丙酸氯倍他索（CP）是一种超强效外用糖皮质激素，因其具有强大的抗炎、止痒、血管收缩和抗增殖活性，被广泛用于各种皮肤疾病的治疗。安全性研究表明，CP在较短时间内使用更安全，然而，长期使用会出现如光敏性、库欣样综合征、过敏性接触性皮炎、骨坏死、色素减退、类固醇性痤疮和皮肤萎缩等副作用。因此，美国食品药品监督管理局（US FDA）已将CP的使用限制在不超过15天。研究科学家通过将其纳入新型纳米递送平台，解决了它的几种制剂和药物递送问题，如低水溶性、稳定性差、光降解和吸收不良等。利用这些技术，CP的这些缺点在很大程度上得到了解决，从而重新确立了该药物的地位。本文探讨了CP的物理化学性质和作用机制。此外，还尝试发现并突出报道的用于CP的新型纳米系统的可能特性，包括纳米乳剂、纳米海绵、固体脂质纳米粒、纳米结构脂质载体和纳米凝胶。同时也讨论了CP的稳定性、安全性问题及其商业地位。
